Novo Nordisk to announce comparative data on semaglutide and resmetirom in MASH
Novo Nordisk says it will announce comparative data on semaglutide and resmetirom in MASH.
Related stories
Universal Music Group Q3 Revenue Rises 12.3%, Adjusted EBITDA 9%
Universal Music Group reported third-quarter revenue of €3.39 billion, up 12.3%, and adjusted EBITDA growth of 9%. Subscription growth, physical music sales and its Downtown acquis
M impact | EQUITY | Oct 29, 2026, 06:34 PM UTC
Weil Gotshal Plans to Wind Down Amid Partner Exodus
The prominent US law firm is planning to dissolve, setting up decisions involving its lawyers, clients and rival firms.
L impact | EQUITY | Oct 29, 2026, 06:31 PM UTC
US session market picture: S&P 500 -0.64%, Nasdaq 100 -1.69%; EUR/USD +0.1%, WTI -0.7%, WBD leads volume
US session market picture. US index futures: S and P futures is down 0.64 percent, Nasdaq futures is down 1.69 percent, Dow futures is down 0.64 percent and Russell futures is up 0
M impact | EQUITY | Oct 29, 2026, 06:30 PM UTC
Wall Street Slides as Alphabet Revenue Miss Revives AI Spending Jitters
U.S. stocks retreated Thursday as investors reassessed big tech’s AI spending after earnings, inflation data and the Federal Reserve’s policy decision.
M impact | EQUITY | Oct 29, 2026, 06:27 PM UTC
Alnylam Shares Fall About 26% on Demand and Pipeline Concerns
Alnylam signaled slower-than-expected demand growth for AMVUTTRA and pushed back certain trial results, while citing near-term Medicare Advantage restrictions and proposed drug rei
M impact | EQUITY | Oct 29, 2026, 06:26 PM UTC
Alphabet Shares Fall More Than 10%, Weighing on Nasdaq
Alphabet shares fell more than 10% Thursday after quarterly earnings missed Wall Street expectations, renewing concerns about returns on AI spending. The Nasdaq 100 fell about 1.3%
M impact | EQUITY | Oct 29, 2026, 06:26 PM UTC